Journal of Cancer Immunology
Higher Frequency and Poor Prognosis with COVID-19 Associated Cytokine Storm among Cancer Patients: Between Two Fires
At the end of 2019, the world faced a new disease, COVID-19 caused by SARS-Cov-2 and became a pandemic within few weeks. The fact that COVID-19 spreads very quickly and has
significant morbidity and mortality had devastating effects all over the world.
Can Butein be a Future Candidate for the Treatment of Advance Metastatic Thyroid Cancer?
The incidence and prevalence of papillary thyroid cancer (PTC) are increasing worldwide and it is the 5th most common endocrine cancer in females.J Cancer Immunol, 2022, Volume 4, Issue 2, p43-46 | DOI: 10.33696/cancerimmunol.4.064
Performance of the Tyrer-Cuzick 8 Breast Cancer Risk Model Across Races: A Review
The Tyrer-Cuzick (TC) model is a breast cancer risk assessment tool that provides women with their risk of developing breast cancer based on genetic and personal factors. The most recent version of the TC model, TC8, is the first version to include breast density as a risk factor for breast cancer.J Cancer Immunol, 2022, Volume 4, Issue 2, p47-51 | DOI: 10.33696/cancerimmunol.4.065
Clutch Control: Changing the Speed and Direction of CAR-T Cell Therapy
The adoptive transfer of T cells expressing chimeric antigen receptors (CAR-T cells) has revolutionized the treatment of hematological malignancies, providing unmatched clinical responses in adults and children with relapsed or refractory B cell malignancies.J Cancer Immunol, 2022, Volume 4, Issue 2, p52-59 | DOI: 10.33696/cancerimmunol.4.066
Molecular Iodine Misconceptions: A Novel Formulation Approach to Topical Iodine
My team of chemists have formulated molecular iodine (I2) so it can be studied independent of other iodine species.The initial impetus for this effort was to allow for a higher concentration of biocidal I2 that would not evaporate into the atmosphere when applied to skin.J Cancer Immunol, 2022, Volume 4, Issue 2, p60-64 | DOI: 10.33696/cancerimmunol.4.067
A Surprising Benefit of Cysteine Capping for Antibody Drug Conjugates
Antibody-drug conjugates (ADCs), combining the best features of monoclonal antibodies and small molecule drugs, are considered the “guided missiles” for cancer therapy, with eleven FDA-approved products. Yet the ADC modality still presents a huge challenge to drug developers, especially for targeting tumors with low abundance and/or heterogeneity of tumor-associated antigens.J Cancer Immunol, 2022, Volume 4, Issue 2, p65-70 | DOI: 10.33696/cancerimmunol.4.068
Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.